Akero Therapeutics, Inc.
AKRO
$41.00
$0.010.02%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -7.80% | -9.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.50% | 24.28% | |||
| Operating Income | 4.50% | -24.28% | |||
| Income Before Tax | 3.69% | -29.86% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 3.69% | -29.86% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 3.69% | -29.86% | |||
| EBIT | 4.50% | -24.28% | |||
| EBITDA | 4.52% | -24.28% | |||
| EPS Basic | 5.23% | -29.34% | |||
| Normalized Basic EPS | 18.92% | -29.33% | |||
| EPS Diluted | 5.23% | -29.26% | |||
| Normalized Diluted EPS | 18.92% | -29.33% | |||
| Average Basic Shares Outstanding | 1.63% | 0.41% | |||
| Average Diluted Shares Outstanding | 1.63% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||